187 related articles for article (PubMed ID: 31559605)
21. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
22. Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.
Kim D; Kim W; Joo SK; Han J; Kim JH; Harrison SA; Younossi ZM; Ahmed A
J Gastroenterol; 2020 Mar; 55(3):330-341. PubMed ID: 31535207
[TBL] [Abstract][Full Text] [Related]
23. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
27. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
28. Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study.
Zhou J; Liu J; Sheng H; You N; Chen J; Mi X; Yang W; Zang S; Shi J;
Adv Ther; 2019 Apr; 36(4):880-895. PubMed ID: 30820874
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.
Wei JL; Leung JC; Loong TC; Wong GL; Yeung DK; Chan RS; Chan HL; Chim AM; Woo J; Chu WC; Wong VW
Am J Gastroenterol; 2015 Sep; 110(9):1306-14; quiz 1315. PubMed ID: 26215532
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
31. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.
Petta S; Vanni E; Bugianesi E; Rosso C; Cabibi D; Cammà C; Di Marco V; Eslam M; Grimaudo S; Macaluso FS; McLeod D; Pipitone RM; Abate ML; Smedile A; George J; Craxì A
Aliment Pharmacol Ther; 2015 May; 41(10):939-48. PubMed ID: 25801076
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.
Schmitz SM; Kroh A; Ulmer TF; Andruszkow J; Luedde T; Brozat JF; Neumann UP; Alizai PH
BMC Gastroenterol; 2020 Aug; 20(1):254. PubMed ID: 32758151
[TBL] [Abstract][Full Text] [Related]
33. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.
Nobili V; Mantovani A; Cianfarani S; Alisi A; Mosca A; Sartorelli MR; Maffeis C; Loomba R; Byrne CD; Targher G
J Hepatol; 2019 Oct; 71(4):802-810. PubMed ID: 31279904
[TBL] [Abstract][Full Text] [Related]
36. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver.
Alam S; Islam MS; Islam S; Mustafa G; Saleh AA; Ahmad N
Indian J Gastroenterol; 2017 Sep; 36(5):366-372. PubMed ID: 28975533
[TBL] [Abstract][Full Text] [Related]
37. Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages.
Shi YW; Wang QY; Zhao XY; Sun YM; Kong YY; Ou XJ; Jia JD; Wu SS; You H
J Dig Dis; 2020 May; 21(5):279-286. PubMed ID: 32336033
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease (NAFLD) in lean individuals - Single centre large cohort clinicopathologic and immunophenotypic study.
Rastogi A; Rath I; Varadarajan A; Ramakrishna G; Bihari C; Maiwall R
Pathol Res Pract; 2022 Oct; 238():154112. PubMed ID: 36126451
[TBL] [Abstract][Full Text] [Related]
39. Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up.
Holmer M; Ekstedt M; Nasr P; Zenlander R; Wester A; Tavaglione F; Romeo S; Kechagias S; Stål P; Hagström H
Liver Int; 2022 Dec; 42(12):2769-2780. PubMed ID: 36166317
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
Santiago-Rolón A; Purcell D; Rosado K; Toro DH
P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
